A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Zhao, Hongyun
Zhang, Zhonghan
Luo, Fan
Ma, Yuxiang
Fang, Wenfeng
Yang, Yunpeng
Zhang, Yang
Huang, Yan
Zhang, Li
机构：
[1] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS9116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9116
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II
    Mok, Tony
    Wu, Yi Long
    Thongprasert, Sumitra
    Yu, Chong-Jen
    Zhang, Li
    Ladrera, Guia Elena
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Sandoval-Tan, Jennifer
    Zhu, Yunzhong
    Liao, Meilin
    Zhou, Caicun
    Pan, Hongming
    Lee, Victor
    Chen, Yuh-Min
    Sun, Yan
    Margono, Benjamin
    Jin, Kate
    Truman, Matt
    Lee, Jin Soo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
    Seckl, Michael J.
    Ottensmeier, Christian
    Cullen, Michael
    Schmid, Peter
    James, Lindsay
    Wadsworth, Christina
    Farrant, Hannah
    Muthukumar, Dakshinamoorthy
    Thompson, Joyce
    Harden, Susan
    Middleton, Gary
    Fife, Kate
    Crosse, Barbara
    Taylor, Paul
    Khan, Ifty
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S219 - S219
  • [23] A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) WITH EITHER BEVACIZUMAB plus PLATINUM plus PACLITAXEL OR PEMETREXED plus PLATINUM AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wakelee, H.
    Yu, W.
    Rittweger, K.
    Paton, V. E.
    ANNALS OF ONCOLOGY, 2012, 23 : 445 - 445
  • [24] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
    Hu, Y.
    Zhang, F.
    Zhao, M.
    Zheng, Z.
    Zhang, H.
    Jiang, T.
    Liu, Z.
    Wen, J.
    Gan, X.
    Wang, H.
    Wu, L.
    Cang, S.
    Zhao, J.
    Li, X.
    Peng, L.
    Fan, Z.
    Shen, G.
    Zhou, Q.
    Zou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1312 - S1312
  • [25] Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    Ohtsu, Atsushi
    Shah, Manish A.
    Van Cutsem, Eric
    Rha, Sun Young
    Sawaki, Akira
    Park, Sook Ryun
    Lim, Ho Yeong
    Yamada, Yasuhide
    Wu, Jian
    Langer, Bernd
    Starnawski, Michal
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 3968 - 3976
  • [26] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Tran, Hai T.
    Zinner, Ralph G.
    Blumenschein, George R., Jr.
    Oh, Yun W.
    Papadimitrakopoulou, Vassiliki A.
    Kim, Edward S.
    Lu, Charles
    Malik, Mubashira
    Lum, Bert L.
    Herbst, Roy S.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (03) : 499 - 505
  • [27] Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)
    Hai T. Tran
    Ralph G. Zinner
    George R. Blumenschein
    Yun W. Oh
    Vassiliki A. Papadimitrakopoulou
    Edward S. Kim
    Charles Lu
    Mubashira Malik
    Bert L. Lum
    Roy S. Herbst
    Investigational New Drugs, 2011, 29 : 499 - 505
  • [28] An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC).
    Scagliotti, G.
    Vynnychenko, I.
    Ichinose, Y.
    Park, K.
    Kubota, K.
    Blackhall, F. H.
    Pirker, R.
    Galiulin, R.
    Ciuleanu, T.
    Sydorenko, O.
    Dediu, M.
    Papai-Szekely, Z.
    Banaclocha, N. Martinez
    McCoy, S.
    Yao, B.
    Hei, Y. J.
    Spigel, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [29] An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)
    Scagliotti, G.
    Vynnychenko, I.
    Ichinose, Y.
    Park, K.
    Kubota, K.
    Blackhall, F. H.
    Pirker, R.
    Galiulin, R.
    Ciuleanu, T.
    Sydorenko, O.
    Dediu, M.
    Papai-Szekely, Z.
    Banaclocha, N. Martinez
    Mccoy, S.
    Yao, B.
    Hei, Y. J.
    Spigel, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [30] A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)
    Zhang, L.
    Fang, W.
    Yu, Q.
    Zhang, H.
    Wu, G.
    Wu, D.
    Lin, Y.
    Zhu, J.
    Chen, J.
    Hu, X.
    Lan, B.
    Zhou, Z.
    Lin, H.
    Wang, Z.
    Lei, X.
    Pan, S.
    Chen, L.
    Zhang, J.
    Kong, T.
    Yu, H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1562 - S1562
12345